Advertisement Pharmaceutical Business review - Page 194 of 5218 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 2, 2024

Health Canada grants approval for Celltrion’s Steqeyma for multiple conditions

Health Canada has granted approval for Celltrion Healthcare Canada’s Steqeyma (ustekinumab injection) and Steqeyma IV (ustekinumab for injection, solution for intravenous infusion) for treating various chronic inflammatory conditions.

The treatment is authorised for use in adults with active Crohn's disease, plaque psoriasis, and active psoriatic arthritis. Credit: Eszter Miller from Pixabay.